Drugs / GM-K562/leukemia cell vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00809250 | Nov 2008 → May 2011 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome with excess blasts | Dana-Farber Cancer Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GM-K562/leukemia cell vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00809250 ↗ |
| Modality | Vaccine | “The GM-K562/leukemia cell vaccine is composed of a cultured cell line” NCT00809250 ↗ |
| Route | Subcutaneous | “under the skin” NCT00809250 ↗ |